{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:32:11Z","timestamp":1787959931611,"version":"build-2784847793"},"reference-count":22,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Background: Intravenous vancomycin remains a key agent in the treatment of complex orthopedic infections, particularly those involving methicillin-resistant Staphylococcus aureus (MRSA). However, its use is associated with significant risks, most notably nephrotoxicity. Despite guideline recommendations, standardized dosing and monitoring protocols are often absent in orthopedic settings, leading to inconsistent therapeutic drug exposure and preventable adverse events. This study evaluated the clinical impact of implementing a structured standard operating procedure (SOP) for intravenous vancomycin therapy in orthopedic inpatients. Methods: We conducted a single-center, pre-post cohort study at a university orthopedic department. The intervention consisted of a standard operating procedure (SOP) for intravenous vancomycin therapy, which mandated weight-based loading doses, renal function-adjusted maintenance dosing, trough level monitoring, and defined dose adjustments. Patients treated before SOP implementation (n = 58) formed the control group; those treated under the SOP (n = 56) were prospectively included. The primary outcome was the incidence of vancomycin-associated acute kidney injury (VA-AKI) defined by KDIGO Stage 1 criteria. Secondary outcomes included therapeutic trough level attainment and infusion-related or ototoxic adverse events. Results: All patients in the post-SOP group received a loading dose (100% vs. 31% pre-SOP, p &lt; 0.001). The range of measured vancomycin trough levels narrowed substantially after SOP implementation (7.1\u201336.2 mg\/L vs. 4.0\u201380.0 mg\/L). The proportion of patients reaching therapeutic trough levels increased, although this was not statistically significant. Most notably, VA-AKI occurred in 17.2% of patients in the control group, but in none of the patients after SOP implementation (0%, p = 0.0013). No cases of ototoxicity were observed in either group. Infusion-related reactions decreased after the implementation of the SOP, though not significantly. Conclusions: The introduction of a structured vancomycin protocol significantly reduced adverse drug events and improved dosing control in orthopedic inpatients. Incorporating such protocols into routine practice represents a feasible and effective strategy to strengthen antibiotic stewardship and clinical quality in surgical disciplines.<\/jats:p>","DOI":"10.3390\/antibiotics14080775","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T10:13:51Z","timestamp":1754475231000},"page":"775","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Optimizing Safety and Efficacy of Intravenous Vancomycin Therapy in Orthopedic Inpatients Through a Standardized Dosing Protocol: A Pre-Post Cohort Study"],"prefix":"10.3390","volume":"14","author":[{"given":"Moritz","family":"Diers","sequence":"first","affiliation":[{"name":"Department of Orthopaedic, and Trauma Surgery, Martin-Luther-University Halle-Wittenberg, 06120 Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"Beschauner","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic, and Trauma Surgery, Martin-Luther-University Halle-Wittenberg, 06120 Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Felsberg","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic, and Trauma Surgery, Martin-Luther-University Halle-Wittenberg, 06120 Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Zeh","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic, and Trauma Surgery, Martin-Luther-University Halle-Wittenberg, 06120 Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4691-3588","authenticated-orcid":false,"given":"Karl-Stefan","family":"Delank","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic, and Trauma Surgery, Martin-Luther-University Halle-Wittenberg, 06120 Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Gutteck","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic, and Trauma Surgery, Martin-Luther-University Halle-Wittenberg, 06120 Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3309-6260","authenticated-orcid":false,"given":"Felix","family":"Werneburg","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic, and Trauma Surgery, Martin-Luther-University Halle-Wittenberg, 06120 Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jinf.2018.07.014","article-title":"Clinical outcome and risk factors for failure in late acute prosthetic joint infections treated with debridement and implant retention","volume":"78","author":"Sebillotte","year":"2019","journal-title":"J. Infect."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1017\/ice.2021.65","article-title":"Incidence and burden of Staphylococcus aureus infection after orthopedic surgeries","volume":"43","author":"Dreyfus","year":"2022","journal-title":"Infect. Control. Hosp. Epidemiol."},{"key":"ref_3","unstructured":"European Centre for Disease Prevention and Control (2022). Antimicrobial Resistance Surveillance in Europe 2022\u20132020 Data, ECDC."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s40121-019-00278-1","article-title":"A Multicenter Evaluation of Vancomycin-Associated Acute Kidney Injury in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections","volume":"9","author":"Jorgensen","year":"2020","journal-title":"Infect. Dis. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/phar.1428","article-title":"Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin\u2013tazobactam or with cefepime","volume":"34","author":"Gomes","year":"2014","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"ref_7","first-page":"511","article-title":"The whole price of vancomycin: Toxicities, troughs, and time","volume":"80","author":"Jeffres","year":"2020","journal-title":"Drugs"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/phar.2722","article-title":"AUC vs trough-based vancomycin dosing and AKI risk: A systematic review","volume":"42","author":"Abdelmessih","year":"2022","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/phar.2376","article-title":"Therapeutic monitoring of vancomycin for serious MRSA infections: A revised consensus guideline","volume":"40","author":"Rybak","year":"2020","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Hall, R.G., Hazlewood, K.A., Brouse, S.D., Giuliano, C.A., Haase, K.K., Frei, C.R., Forcade, N.A., Bell, T., Bedimo, R.J., and Alvarez, C.A. (2013). Empiric guideline-recommended weight-based vancomycin dosing and nephrotoxicity rates in patients with methicillin-resistant Staphylococcus aureus bacteremia: A retrospective cohort study. BMC Pharmacol. Toxicol., 14.","DOI":"10.1186\/2050-6511-14-12"},{"key":"ref_11","first-page":"145","article-title":"Pharmacist-led implementation of a vancomycin guideline across medical and surgical units: Impact on clinical behavior and therapeutic drug monitoring outcomes","volume":"4","author":"Phillips","year":"2015","journal-title":"Integr. Pharm. Res. Pract."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"100254","DOI":"10.1016\/j.infpip.2022.100254","article-title":"Implementation of a hospital antimicrobial stewardship program to improve vancomycin use in Cyprus: Challenges and opportunity","volume":"4","author":"Papastergiou","year":"2022","journal-title":"Infect. Prev. Pract."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Baiocco, G.G., Greiner, S., Rosa, M.B., Flores, C.D., and Barros, H.M.T. (2023). Impact of implementing a vancomycin protocol to reduce kidney toxicity: A comparative study. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1154573"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jiac.2020.10.014","article-title":"Comparison of trough concentration and area under the curve of vancomycin associated with the incidence of nephrotoxicity and predictors of a high trough level","volume":"27","author":"Suzuki","year":"2021","journal-title":"J. Infect. Chemother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e1327","DOI":"10.5435\/JAAOS-D-21-00722","article-title":"Antimicrobial Stewardship in Total Joint Arthroplasty: Outcomes of a Collaborative Program Implementation","volume":"30","author":"Hyland","year":"2022","journal-title":"J. Am. Acad. Orthop. Surg."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1093\/jac\/dkw166","article-title":"Reduction in post-operative acute kidney injury following a change in antibiotic prophylaxis policy for orthopaedic surgery: An observational study","volume":"71","author":"Walker","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.jinf.2022.06.029","article-title":"Assessment of an institutional guideline for vancomycin dosing and identification of predictive factors associated with dose and drug trough levels","volume":"85","author":"Gu","year":"2022","journal-title":"J. Infect."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1017\/ice.2021.296","article-title":"Effectiveness of a vancomycin dosing protocol guided by area under the concentration-time curve to minimal inhibitory concentration (AUC\/MIC) with multidisciplinary team support to improve hospital-wide adherence to a vancomycin dosing protocol: A pilot study","volume":"43","author":"Katawethiwong","year":"2022","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Angelini, J., Giuliano, S., Russiani, F., Lo Re, F., Flammini, S., Cadeo, B., Martini, L., Tascini, C., and Baraldo, M. (2025). PK\/PD Analysis of High-Dose Daptomycin Use in the Treatment of Bone and Joint Infections: Data from a Real-World Setting. Microorganisms, 13.","DOI":"10.3390\/microorganisms13020304"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Clifford, K.M., Selby, A.R., Reveles, K.R., Teng, C., Hall, R.G., McCarrell, J., and Alvarez, C.A. (2022). The Risk and Clinical Implications of Antibiotic-Associated Acute Kidney Injury: A Review of the Clinical Data for Agents with Signals from the Food and Drug Administration\u2019s Adverse Event Reporting System (FAERS) Database. Antibiotics, 11.","DOI":"10.3390\/antibiotics11101367"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Pupaibool, J. (2024). The Role of Rifampin in Prosthetic Joint Infections: Efficacy, Challenges, and Clinical Evidence. Antibiotics, 13.","DOI":"10.3390\/antibiotics13121223"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"ofae217","DOI":"10.1093\/ofid\/ofae217","article-title":"Counting the Cost of Daptomycin Versus Vancomycin in Hospitalized Patients: A Cost Minimization Analysis","volume":"11","author":"Wagner","year":"2024","journal-title":"Open Forum Infect. Dis."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/8\/775\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:19:36Z","timestamp":1760033976000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/8\/775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":22,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["antibiotics14080775"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics14080775","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,31]]}}}